Additional Local Consolidative Therapy Showed Survival Benefit Than EGFR-TKIs Alone in Bone Oligometastatic Lung Adenocarcinoma Patients

被引：0

作者：

Hu, F. ^{[1
]}

Li, C. ^{[1
]}

Xu, J. ^{[1
]}

Guo, J. ^{[1
]}

Shen, Y. ^{[1
]}

Nie, W. ^{[1
]}

Zheng, X. ^{[1
]}

Wang, L. ^{[2
]}

Zhang, H. ^{[1
]}

Han, B. ^{[1
]}

Zhang, X. ^{[1
]}

机构：

[1] Shanghai Jiao Tong Univ, Shanghai Chest Hosp, Dept Pulm, Shanghai, Peoples R China

[2] Tongji Univ, Shanghai Pulm Hosp, Integrated Tem & Western Med Dept, Shanghai, Peoples R China

来源：

JOURNAL OF THORACIC ONCOLOGY | 2019年 / 14卷 / 10期

关键词：

Bone oligometastases; Local consolidative therapy; Epidermal growth factor receptor mutation;

D O I：

10.1016/j.jtho.2019.08.500

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

MA01.10

引用

页码：S251 / S251

页数：1

共 50 条

[1] Additional local consolidative therapy has survival benefit over EGFR tyrosine kinase inhibitors alone in bone oligometastatic lung adenocarcinoma patients
Hu, Fang
Li, Changhui
Xu, Jianlin
Guo, Jindong
Shen, Yinchen
Nie, Wei
Zheng, Xiaoxuan
Wang, Lixin
Zhang, Hai
Han, Baohui
Zhang, Xueyan
LUNG CANCER, 2019, 135 : 138 - 144
[2] EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
Jiang, Tao
Chu, Qian
Wang, Huijuan
Zhou, Fei
Gao, Guanghui
Chen, Xiaoxia
Li, Xuefei
Zhao, Chao
Xu, Qinghua
Li, Wei
Wu, Fengying
Xiong, Anwen
Zhao, Jing
Xu, Yaping
Su, Chunxia
Ren, Shengxiang
Zhou, Caicun
Hirsch, Fred R.
INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (10) : 2605 - 2612
[3] EGFR-TKIs plus local therapy demonstrated survival benefit than TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases
Jiang, T.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (04) : S74 - S74
[4] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with multiple brain metastases
Jiang, T.
Zhou, C.
ANNALS OF ONCOLOGY, 2019, 30
[5] EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases
Jiang, Tao
Zhang, Yongchang
Li, Xuefei
Zhao, Chao
Chen, Xiaoxia
Su, Chunxia
Ren, Shengxiang
Yang, Nong
Zhou, Caicun
EUROPEAN JOURNAL OF CANCER, 2019, 121 : 98 - 108
[6] Consolidative Local Ablative Therapy Improves the Survival of Patients With Synchronous Oligometastatic NSCLC Harboring EGFR Activating Mutation Treated With First-Line EGFR-TKIs
Xu, Qinghua
Zhou, Fei
Liu, Hui
Jiang, Tao
Li, Xuefei
Xu, Yaping
Zhou, Caicun
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (09) : 1383 - 1392
[7] Efficacy of Local Consolidative Therapy for Oligometastatic Lung Adenocarcinoma Patients Harboring EGFR Mutations.
Hu, F.
Xu, J.
Zhang, B.
Li, C.
Nie, W.
Gu, P.
Hu, P.
Wang, H.
Zhang, Y.
Shen, Y.
Wang, S.
Han, B.
Zhang, X.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S337 - S337
[8] Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
Chen, Yanxin
Wei, Jianping
Cai, Jing
Liu, Anwen
BMC CANCER, 2019, 19 (01)
[9] Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
Yanxin Chen
Jianping Wei
Jing Cai
Anwen Liu
BMC Cancer, 19
[10] Local Ablative Therapy Improves Survival in Patients with Synchronous Oligometastatic NSCLC Harboring EGFR Mutation Treated with EGFR-TKIs
Xu, Q.
Zhou, F.
Liu, H.
Xu, Y.
Zhou, C.
JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S337 - S337

← 1 2 3 4 5 →